Evidence map›Paper›PMID 30212638›Full record

ArticleJournal of the Royal Society of Medicine2018

UK newspaper reporting of the NHS cancer drugs fund, 2010 to 2015: a retrospective media analysis.

Grant Lewison, Ajay Aggarwal, Philip Roe, Henrik Møller, Charlotte Chamberlain, Richard Sullivan

Abstract read
In one paragraph

Article in Journal of the Royal Society of Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. NHS cancer drugs fund.Journal of the Royal Society of Medicine · 2019
    Article
  4. Impact of reduced working hours on the NHS.Journal of the Royal Society of Medicine · 2019
    Article
  5. The seductive hope of cancer therapies.Journal of the Royal Society of Medicine · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Grant Lewison1 King's Health Partners Comprehensive Cancer Centre, Institute of Cancer Policy, School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London SE1 9RT, UK.ORCID https://orcid.org/0000-0002-4493-1216
Ajay Aggarwal1 King's Health Partners Comprehensive Cancer Centre, Institute of Cancer Policy, School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London SE1 9RT, UK.
Philip Roe2 Evaluametrics Ltd, St Albans AL3 4DW, UK.
Henrik Møller1 King's Health Partners Comprehensive Cancer Centre, Institute of Cancer Policy, School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London SE1 9RT, UK.
Charlotte Chamberlain3 Bristol Medical School: Population Health Sciences, University of Bristol, Bristol BS8 2 PS, UK.
Richard Sullivan1 King's Health Partners Comprehensive Cancer Centre, Institute of Cancer Policy, School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London SE1 9RT, UK.

Funding

Department of Health DRF-2014-07-064Medical Research Council MR/K023233/1
6 · The paper itself

Abstract

Objective We wished to explore how UK national newspapers had covered the creation and operation of the Cancer Drugs Fund from 2010 to 2015. This was introduced to provide cancer patients in England with access to drugs not appraised or approved by the National Institute for health and Care Excellence. Design We sought stories in nine newspapers from the Factiva database, and copied their salient details to a spreadsheet. They were categorised by whether they were supportive or critical of the Cancer Drugs Fund and their main arguments, which drugs they mentioned and for which cancers. Settings Not applicable Participants Not applicable Main outcome results Press coverage was mainly very positive, arguing for the Cancer Drugs Fund's extension to Scotland and Wales, and a bigger budget, but neglecting the lack of patient benefit and the severe side effects that sometimes occurred. Leading this support was the Daily Mail, whose influence (measured by the product of number of stories and the paper's circulation) was almost greater than that of the other newspapers combined. Results Press coverage was mainly very positive, arguing for the Cancer Drugs Fund's extension to Scotland and Wales, and a bigger budget, but neglecting the lack of patient benefits and the severe side effects that sometimes occurred. Leading this support was the Daily Mail, whose influence (measured by the product of number of stories and the paper's circulation) was almost greater than that of the other newspapers combined. Conclusions Although there was some critical analysis of the Cancer Drugs Fund, our analysis shows that most press coverage was largely positive and unrepresentative in comparison with the lack of overall benefits to patients and society. It is likely that it contributed to the Cancer Drugs Fund's continuation despite mounting evidence of its ineffectiveness.

Indexed as

Drug ApprovalHealth Services AccessibilityMass MediaNewspapers as TopicState MedicineAntineoplastic AgentsAttitude to HealthGovernmentHumansNeoplasmsPublic OpinionQuality of Health CareRetrospective StudiesUnited KingdomAntineoplastic Agentschemotherapydrugs and medicinesEffectiveness of caremedicines regulationoncology

Identifiers

PMID30212638
PMCPMC6194957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.